Summit Therapeutics Inc 2024年度报告

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes☐No☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of theAct. Yes☐No☐ Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) ofthe Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrantwas required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☐No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months(or for such shorter period that the registrant was required to submit such files). Yes☐No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer,a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,”“accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☐ Accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extendedtransition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessmentof the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financialstatements of the registrant included in the filing reflect the correction of an error to previously issued financialstatements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis ofincentive-based compensation received by any of the registrant’s executive o☐cers during the relevant recoveryperiod pursuant to §240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo☐ The aggregate market value of the voting common stock held by non-affiliates based on the closing stock price onJune 30, 2024, was $827.3 million. For purposes of this computation only, all executive officers and directors havebeen deemed affiliates. The number of outstanding shares of the registrant’s common stock, par value $0.01 per share, as of February 18,2025 was 737,679,704. Documents Incorporated by ReferencePortions of the registrant’s definitive proxy statement relating to the registrant’s 2025 annual meeting of stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K. The registrant’sdefinitive proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after theend of the fiscal year to which this report relates. TABLE OF CONTENTS Cautionary Note Regarding Forward-Looking Statements PART I Item 1.Business1Item 1A.Risk Factors27Item 1B.Unresolved Staff Comments62Item 1C.Cybersecurity62Item 2.Properties63Item 3.Legal Proceedings63Item 4.Mine Safety Disclosures63 PART II Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters andIssuer Purchases of Equity Securities64Item 6.[Reserved]65Item 7.Management’s Discussion and Analysis of Financial Condition and Resultsof Operations65 Item 7A.Quantitative and Qualitative Disclosures About Market Risk77Item 8.Financial Statements and Supplementary Data78Item 9.Changes in and Disagreements with Accountants on Accounting andFinancial Disclosure78Item 9A.Controls and Procedures78Item 9B.Other Information79Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections79 PART IIIItem 10.Directors, Executive Officers, and Corporate Governance79Item 11.Executive Compensation79Item 12.Security Ownership of Certain Beneficial Owners and Management andRelated Stockholder Matters79Item 13.Certain Relationships and Related Transactions, and DirectorIndependence79Item 14.Principal Accounting Fees and Services79PART IVItem 15.Exhibits, Financial Statement Schedules80Item 16Report Summary84Signatures85 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of the PrivateSecurities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, andSection 21E of the Securit